Our top pick for
Alcon Inc is a medical instruments & supplies business based in the US. Alcon shares (ALC) are listed on the NYSE and all prices are listed in US Dollars. Alcon employs 20,000 staff and has a trailing 12-month revenue of around USD$6.8 billion.
|52-week range||USD$39.37 - USD$76.26|
|50-day moving average||USD$72.2679|
|200-day moving average||USD$63.7533|
|Wall St. target price||USD$69.88|
|Dividend yield||USD$0.196 (0.27%)|
|Earnings per share (TTM)||USD$-1.3031|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Alcon stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alcon's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alcon's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1 billion.
The EBITDA is a measure of a Alcon's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$6.8 billion|
|Gross profit TTM||USD$3.7 billion|
|Return on assets TTM||-0.8%|
|Return on equity TTM||-3.77%|
|Market capitalisation||USD$35.3 billion|
TTM: trailing 12 months
There are currently 5.0 million Alcon shares held short by investors – that's known as Alcon's "short interest". This figure is 18.7% down from 6.1 million last month.
There are a few different ways that this level of interest in shorting Alcon shares can be evaluated.
Alcon's "short interest ratio" (SIR) is the quantity of Alcon shares currently shorted divided by the average quantity of Alcon shares traded daily (recently around 1.1 million). Alcon's SIR currently stands at 4.72. In other words for every 100,000 Alcon shares traded daily on the market, roughly 4720 shares are currently held short.
However Alcon's short interest can also be evaluated against the total number of Alcon shares, or, against the total number of tradable Alcon shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alcon's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Alcon shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Alcon shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alcon.
Find out more about how you can short Alcon stock.
We're not expecting Alcon to pay a dividend over the next 12 months.
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients. It operates through two segments, Surgical and Vision Care. The Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures, such as cataracts, vitreoretinal, refractive laser, and glaucoma surgery. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR ophthalmic microscope, verion imaged guided system, and ORA System for intra-operative measurements and guidance; vitreoretinal products comprising constellation vision system, grieshaber DSP and MIVS instrumentation, ultravit high speed vitrectomy probes, purepoint laser, and NGENUITY 3D visualization system; refractive surgery products, including WaveLight lasers and diagnostics used for LASIK; and glaucoma product, such as EX-PRESS glaucoma filtration device, as well as AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. The Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, including devices and over-the-counter products for dry eye, over-the-counter products for contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers under the TOTAL, PRECISION, Dailies, Air Optix, Systane, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. Alcon, Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.